Annual CFO
$23.33 M
+$95.58 M+132.29%
31 December 2023
Summary:
ProQR Therapeutics NV annual cash flow from operations is currently $23.33 million, with the most recent change of +$95.58 million (+132.29%) on 31 December 2023. During the last 3 years, it has risen by +$77.07 million (+143.41%). PRQR annual CFO is now at all-time high.PRQR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.71 M
-$121.60 K-1.84%
01 September 2024
Summary:
ProQR Therapeutics NV quarterly cash flow from operations is currently -$6.71 million, with the most recent change of -$121.60 thousand (-1.84%) on 01 September 2024. Over the past year, it has increased by +$1.52 million (+18.42%). PRQR quarterly CFO is now -113.98% below its all-time high of $48.04 million, reached on 31 March 2023.PRQR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$35.67 M
+$1.52 M+4.08%
01 September 2024
Summary:
ProQR Therapeutics NV TTM cash flow from operations is currently -$35.67 million, with the most recent change of +$1.52 million (+4.08%) on 01 September 2024. Over the past year, it has dropped by -$43.73 million (-542.79%). PRQR TTM CFO is now -252.91% below its all-time high of $23.33 million, reached on 31 December 2023.PRQR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRQR Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +132.3% | +18.4% | -542.8% |
| 3 y3 years | +143.4% | +24.8% | +25.1% |
| 5 y5 years | +169.3% | +29.2% | +23.6% |
PRQR Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +132.3% | -114.0% | +70.8% | -252.9% | +50.6% |
| 5 y | 5 years | at high | +132.3% | -114.0% | +70.8% | -252.9% | +50.6% |
| alltime | all time | at high | +132.3% | -114.0% | +70.8% | -252.9% | +50.6% |
ProQR Therapeutics NV Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.71 M(+1.8%) | -$35.67 M(-4.1%) |
| June 2024 | - | -$6.59 M(-59.9%) | -$37.19 M(-9.6%) |
| Mar 2024 | - | -$16.44 M(+177.3%) | -$41.14 M(-276.4%) |
| Dec 2023 | $23.33 M(-132.3%) | -$5.93 M(-28.0%) | $23.33 M(+189.6%) |
| Sept 2023 | - | -$8.23 M(-22.0%) | $8.06 M(+182.6%) |
| June 2023 | - | -$10.55 M(-122.0%) | $2.85 M(-328.9%) |
| Mar 2023 | - | $48.04 M(-326.6%) | -$1.25 M(-98.3%) |
| Dec 2022 | -$72.25 M(+134.7%) | -$21.20 M(+57.8%) | -$72.25 M(+54.7%) |
| Sept 2022 | - | -$13.44 M(-8.3%) | -$46.69 M(+10.7%) |
| June 2022 | - | -$14.65 M(-36.2%) | -$42.19 M(+6.6%) |
| Mar 2022 | - | -$22.97 M(-627.3%) | -$39.57 M(+28.6%) |
| Dec 2021 | -$30.78 M(-42.7%) | $4.36 M(-148.8%) | -$30.78 M(-35.3%) |
| Sept 2021 | - | -$8.93 M(-25.7%) | -$47.59 M(-8.2%) |
| June 2021 | - | -$12.03 M(-15.1%) | -$51.87 M(+1.0%) |
| Mar 2021 | - | -$14.17 M(+13.7%) | -$51.36 M(-4.4%) |
| Dec 2020 | -$53.74 M(+9.2%) | -$12.46 M(-5.7%) | -$53.74 M(-2.1%) |
| Sept 2020 | - | -$13.21 M(+14.7%) | -$54.91 M(+7.3%) |
| June 2020 | - | -$11.52 M(-30.5%) | -$51.19 M(-1.1%) |
| Mar 2020 | - | -$16.56 M(+21.5%) | -$51.74 M(+5.1%) |
| Dec 2019 | -$49.22 M | -$13.63 M(+43.6%) | -$49.22 M(+5.4%) |
| Sept 2019 | - | -$9.49 M(-21.4%) | -$46.69 M(+12.0%) |
| June 2019 | - | -$12.07 M(-14.1%) | -$41.68 M(+16.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$14.04 M(+26.6%) | -$35.76 M(+6.3%) |
| Dec 2018 | -$33.64 M(-15.0%) | -$11.10 M(+147.9%) | -$33.64 M(+7.5%) |
| Sept 2018 | - | -$4.48 M(-27.1%) | -$31.29 M(-15.8%) |
| June 2018 | - | -$6.14 M(-48.5%) | -$37.16 M(-11.9%) |
| Mar 2018 | - | -$11.93 M(+36.5%) | -$42.15 M(+6.5%) |
| Dec 2017 | -$39.58 M(+4.5%) | -$8.74 M(-15.6%) | -$39.58 M(+2.3%) |
| Sept 2017 | - | -$10.35 M(-7.1%) | -$38.70 M(-3.7%) |
| June 2017 | - | -$11.14 M(+19.1%) | -$40.18 M(+3.9%) |
| Mar 2017 | - | -$9.36 M(+19.1%) | -$38.66 M(+2.1%) |
| Dec 2016 | -$37.87 M(+40.8%) | -$7.86 M(-33.6%) | -$37.87 M(+1.0%) |
| Sept 2016 | - | -$11.83 M(+22.9%) | -$37.51 M(+14.7%) |
| June 2016 | - | -$9.62 M(+12.3%) | -$32.71 M(+10.9%) |
| Mar 2016 | - | -$8.57 M(+14.4%) | -$29.51 M(+9.7%) |
| Dec 2015 | -$26.89 M(+39.9%) | -$7.49 M(+6.5%) | -$26.89 M(+3.1%) |
| Sept 2015 | - | -$7.03 M(+9.6%) | -$26.07 M(+6.4%) |
| June 2015 | - | -$6.42 M(+7.8%) | -$24.50 M(+8.7%) |
| Mar 2015 | - | -$5.95 M(-10.7%) | -$22.52 M(+17.2%) |
| Dec 2014 | -$19.23 M(+520.8%) | -$6.67 M(+22.2%) | -$19.23 M(+53.1%) |
| Sept 2014 | - | -$5.46 M(+22.7%) | -$12.56 M(+76.9%) |
| June 2014 | - | -$4.45 M(+67.7%) | -$7.10 M(+167.7%) |
| Mar 2014 | - | -$2.65 M | -$2.65 M |
| Dec 2013 | -$3.10 M | - | - |
FAQ
- What is ProQR Therapeutics NV annual cash flow from operations?
- What is the all time high annual CFO for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV annual CFO year-on-year change?
- What is ProQR Therapeutics NV quarterly cash flow from operations?
- What is the all time high quarterly CFO for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV quarterly CFO year-on-year change?
- What is ProQR Therapeutics NV TTM cash flow from operations?
- What is the all time high TTM CFO for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV TTM CFO year-on-year change?
What is ProQR Therapeutics NV annual cash flow from operations?
The current annual CFO of PRQR is $23.33 M
What is the all time high annual CFO for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high annual cash flow from operations is $23.33 M
What is ProQR Therapeutics NV annual CFO year-on-year change?
Over the past year, PRQR annual cash flow from operations has changed by +$95.58 M (+132.29%)
What is ProQR Therapeutics NV quarterly cash flow from operations?
The current quarterly CFO of PRQR is -$6.71 M
What is the all time high quarterly CFO for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high quarterly cash flow from operations is $48.04 M
What is ProQR Therapeutics NV quarterly CFO year-on-year change?
Over the past year, PRQR quarterly cash flow from operations has changed by +$1.52 M (+18.42%)
What is ProQR Therapeutics NV TTM cash flow from operations?
The current TTM CFO of PRQR is -$35.67 M
What is the all time high TTM CFO for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high TTM cash flow from operations is $23.33 M
What is ProQR Therapeutics NV TTM CFO year-on-year change?
Over the past year, PRQR TTM cash flow from operations has changed by -$43.73 M (-542.79%)